Suretrace video 4/26/2006
Part 1
James Mackay:
As Chairman I thought it’s a timely program, for me to give you an update of who we are as a company and where I see us going as a company, why I am so excited even more so now than I was a year ago with what we have achieved and the future is very bright for us. I also have read many questions from shareholders and let me first answer some of these questions. With regards to China, why china. I decided to go to China first because I knew if we could secure China with government support in China, therefore we could establish and secure SSTY. We secured that. We went to china we did a joint venture, we got involved. With government support we became established in china and by being established in china I knew then it would be easier for us to deal with the west. And though that as you’ve seen in previous press releases we now have set up TPID-US and in a very short coming period will be TPID - Europe. Now we have three sisters, and truly we can now deliver a world product. And through this world product we can now deliver the world standard that china has so supported us on and I know that china and the west are working on to achieve, so as chairman for SSTY and for TPID and the companies I am very, very excited.
Part 2
315, that has been a question on everyone’s list. The 315 contract is still there we participated in the trial run the trial run was a huge success. The problem from that was it was so successful that the clients wanted not only the label 315 they wanted our s-dna mark directly on their product. That then brought to us its own problem, the size of the contracts, and to deliver these contracts we needed the personnel the expertise to deliver, we needed the new labs in china to deliver. And over the last period you’ve seen that we have employed three key people to work within the organization at the same time in china we have completed the three labs. So we are now in the position to deliver on the product. You now want to look at the individuals we have employed. Richard Bendis, his track record speaks for itself. He’s the ideal person to run the company on a global basis. To be involved with TPID-US, TPID-Beijing and TPID-Europe. He’s the ideal person for (could not understand the word) and for visionary. So he’s key. You take John. John is the key technical expert for this current technology and future technologies as is Richard bendis. You take the third member Frederick, Frederick is ideally placed with his educational background with his English, his Chinese to communicate east and west and also be involved in the development of next generation. That’s why these three people were brought onboard, to deliver a blue chip company to you the shareholders. And now with these people in place, we can now deliver on the 315 contract; we can deliver on other contracts. We now have the personnel in place, we now have the labs in place, we have our kmack completed, we have our scanners upgraded we are now ready to deliver what we have always said we are going to do. We are now ready, finally to deliver and that is why as your Chairman I am really excited.
I am so looking forward to the coming months where we can show you shareholders what we have really been doing and why for us as a company to be involved in china now, with the west, now into Europe and to be involved in the development of a world standard and involved in new gen technologies, which are exciting, advanced for SSTY-TPID and Globe. These companies all interact. Globe for example: its technology will now be transported into china so they cross-fertilize each other. With a key core management group run by Bendis, we can now manage our companies on a more controlled basis, to insure we deliver the quality of product, not only in china not only in America but also in Europe. And that’s what we have been working to achieve and as chairman of SSTY and the companies I am very ecstatic about what’s happening and you I know as the shareholders, as it all unfolds in the coming months, you too will be very happy.
Part 3
